Plexxikon
Merck to test Keytruda combinations
May 8, 2015Sales and Marketing BMS, Daiichi Sankyo, Merck, Plexxikon, keytruda, pembrolizumab
Merck will be teaming up with Daiichi Sankyo’s subsidiary Plexxikon to investigate immunotherapy combinations in cancer. A collaborative clinical trial …
Daiichi Sankyo gains rights to potential blockbuster cancer drug
March 2, 2011Research and Development BRAF protein, Daiichi Sankyo, PLX4032, Plexxikon, melanoma, personalised medicine
Daiichi Sankyo has purchased US-based discovery firm Plexxikon for $805 million, gaining access to its potential blockbuster melanoma drug PLX4032. …
Roche’s melanoma candidate impresses in phase II trials
November 5, 2010Research and Development BRAF protein, Cancer, Phase II, Plexxikon, RG7204, Roche
Roche’s mid-stage melanoma candidate has produced positive results in a difficult to treat cancer. RG7204 is an investigational, first-in-class molecule …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
